Top ten healthcare M&A financial and legal advisers for Q1 2019 revealed
JP Morgan was the leading financial adviser globally for mergers and acquisitions (M&A) in Q1 2019 in the healthcare sector, according to GlobalData.
Deals League Tables
Novartis prostate cancer drug gets FDA breakthrough designation
The FDA breakthrough designation is based on positive results from the Phase III VISION study...
Pharma industry venture financing deals in March 2019 total $1.17bn globally
Total pharma industry venture financing deals in March 2019 worth $1.17bn were announced globally, according...
Europe’s pharma industry sees a drop of 11.1% in deal activity in March 2019
Europe's pharma industry saw a drop of 11.1% in deal activity during March 2019, when...
Pharma industry M&A deals in March 2019 total $7.44bn globally
Total pharma industry M&A deals in March 2019 worth $7.44bn were announced globally, according to...
US pharma industry sees a drop of 1.3% in deal activity in March 2019
The US pharma industry saw a drop of 1.3% in overall deal activity during March 2019, when compared with the last 12-month average, according to GlobalData's deals database. Embed this…
North America’s pharma industry sees a drop of 4.8% in deal activity in March 2019
North America's pharma industry saw a drop of 4.8% in deal activity during March 2019, when compared with the last 12-month average, according to GlobalData's deals database. Embed this chart…
Europe’s pharma industry sees a drop of 27.3% in deal activity in Q4 2018
Europe's pharma industry saw a drop of 27.3% in overall deal activity during Q4 2018, when compared to the last four-quarter average, according to GlobalData's deals database. Embed this chart…
North America’s pharma industry sees a rise of 1% in deal activity in Q4 2018
North America's pharma industry saw a rise of 1% in overall deal activity during Q4 2018, when compared to the last four-quarter average, according to GlobalData's deals database. Embed this…
Europe’s pharma industry sees a drop of 3.9% in deal activity in February 2019
Europe's pharma industry saw a drop of 3.9% in deal activity during February 2019, when compared with the last 12-month average, according to GlobalData's deals database. Embed this chart Embed…
North America’s pharma industry sees a drop of 15.7% in deal activity in February 2019
North America's pharma industry saw a drop of 15.7% in deal activity during February 2019, when compared with the last 12-month average, according to GlobalData's deals database. Embed this chart…
